Last reviewed · How we verify
Aromatase Inhibitors, non steroideal
Non-steroidal aromatase inhibitors block the enzyme aromatase, reducing estrogen production in postmenopausal women.
Non-steroidal aromatase inhibitors block the enzyme aromatase, reducing estrogen production in postmenopausal women. Used for Hormone receptor-positive, HER2-negative early breast cancer in postmenopausal women, Advanced or metastatic breast cancer in postmenopausal women.
At a glance
| Generic name | Aromatase Inhibitors, non steroideal |
|---|---|
| Also known as | Femara, Arimidex |
| Sponsor | Fondazione Sandro Pitigliani |
| Drug class | Aromatase Inhibitors, non-steroideal |
| Target | Aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
These inhibitors specifically target the aromatase enzyme, which is responsible for converting androgens into estrogens. By inhibiting this enzyme, they effectively lower estrogen levels, which can slow the growth of hormone-sensitive breast cancers.
Approved indications
- Hormone receptor-positive, HER2-negative early breast cancer in postmenopausal women
- Advanced or metastatic breast cancer in postmenopausal women
Common side effects
- Joint pain
- Hot flashes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: